Sionna Therapeutics, Inc.
- Open
- 5.79
- Day high
- 6.08
- Day low
- 5.75
- Prev close
- 5.87
- Volume
- 1.4M
- Mkt cap
- $273M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.0
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$18.7M over the last 3 months (0 open-market buys, 5 sales)
- 🏛Institutions reducing (13F)
Sionna Therapeutics, Inc. (SION) is a Healthcare company listed on NASDAQ. The stock is down 77% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 5 sales (SEC Form 4).
Sionna Therapeutics, Inc. (SION) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 5 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
SION earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-0.65 | $-0.66 | -1.5% | — | — |
| May 12, 2026 | $-0.52 | $-0.60 | -15.4% | — | — |
| Nov 5, 2025 | $-0.52 | $-0.46 | +11.5% | — | — |
| Mar 20, 2025 | $-0.57 | $-3.38 | -493.0% | — | — |
| Nov 27, 2024 | — | $-0.92 | — | — | — |
SION insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 9, 2026 | Thompson Peter A.director | Sell | 85,918 | $44.86 |
| Jul 9, 2026 | ORBIMED ADVISORS LLCdirector | Sell | 85,918 | $44.86 |
| Jul 7, 2026 | Fitzpatrick Jenniferofficer: Chief Legal Officer | Sell | 10,250 | $43.60 |
| Jul 7, 2026 | Fitzpatrick Jenniferofficer: Chief Legal Officer | Option | 10,250 | $6.11 |
| Jul 2, 2026 | Thompson Peter A.director | Sell | 115,844 | $45.50 |
| Jul 2, 2026 | ORBIMED ADVISORS LLCdirector | Sell | 115,844 | $45.50 |
| Jun 18, 2026 | Stelzer Lauriedirector | Grant | 17,340 | $36.73 |
| Jun 18, 2026 | Thompson Peter A.director | Grant | 17,340 | $36.73 |
| Jun 18, 2026 | Viney Joanne L.director | Grant | 17,340 | $36.73 |
| Jun 18, 2026 | RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner: | Grant | 17,340 | $36.73 |
| Jun 18, 2026 | Booth Brucedirector | Grant | 17,340 | $36.73 |
| Jun 18, 2026 | Clancy Paul Jdirector | Grant | 17,340 | $36.73 |
| Jun 18, 2026 | Resnick Joshuadirector | Grant | 17,340 | $36.73 |
| Jun 18, 2026 | Fleming Harold Edwarddirector | Grant | 17,340 | $36.73 |
| Jun 18, 2026 | Ruddy Marcella K.director | Grant | 17,340 | $36.73 |
Source: SION SEC Form 4 filings, latest Jul 9, 2026. For informational purposes only — not investment advice.
See the full SION insider & 13F page →Sionna Therapeutics, Inc. company profile
Overview
Sionna Therapeutics, Inc. (NASDAQ:SION) is a clinical-stage biopharmaceutical company founded to develop innovative treatments for cystic fibrosis patients. The company emerged from stealth mode and went public, focusing specifically on creating medicines that restore normal function to the defective protein responsible for cystic fibrosis. Sionna represents a specialized player in the rare disease therapeutics space, dedicating its resources entirely to addressing the underlying molecular defects that cause cystic fibrosis rather than just managing symptoms.
Business
Sionna Therapeutics operates in the rare disease biopharmaceutical sector, specifically targeting cystic fibrosis through a novel therapeutic approach. Cystic fibrosis is a genetic disorder affecting approximately 70,000 people worldwide, caused by mutations in the gene that produces the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This protein normally acts as a chloride channel in cell membranes, but when defective, it leads to thick, sticky mucus buildup in the lungs and digestive system, causing progressive lung damage and infections. The company's core focus is developing CFTR modulators - small molecule drugs designed to correct the underlying protein defect rather than merely treating symptoms. These medicines work by either helping the defective CFTR protein fold properly, increasing its function at the cell surface, or both. This represents a precision medicine approach that targets the root cause of the disease at the molecular level. Unlike traditional cystic fibrosis treatments that focus on airway clearance, antibiotics, and enzyme replacement, Sionna's approach aims to normalize CFTR function, potentially offering more comprehensive disease modification. The company appears to be developing treatments for patients with specific CFTR mutations, as different mutations require different therapeutic strategies. This targeted approach reflects the growing understanding that cystic fibrosis is not a single disease but rather a spectrum of conditions requiring personalized treatment approaches.
Revenue model
As a clinical-stage biopharmaceutical company, Sionna currently generates no revenue from product sales, as evidenced by zero revenue across all reported periods. The company operates on a typical biotech business model where it relies on external funding - including venture capital, public offerings, and potentially strategic partnerships - to finance its research and development activities until its drug candidates reach commercialization. Once Sionna's CFTR modulators receive regulatory approval, the company would generate revenue through pharmaceutical product sales to healthcare systems, specialty pharmacies, and patients. The paying customers would primarily be insurance companies, government health programs, and patients with cystic fibrosis. Given the rare disease nature and the precision medicine approach, these drugs would likely command premium pricing, similar to other CFTR modulators in the market. Several factors could significantly impact Sionna's future profitability. Regulatory approval timelines and success rates represent the primary risk, as clinical trial failures or delays can substantially increase development costs. Competition from established players like Vertex Pharmaceuticals, which already markets several CFTR modulators, could pressure pricing and market share. Manufacturing scale and complexity of small molecule drugs will affect gross margins, while the specialized nature of rare disease marketing requires significant investment in medical affairs and patient access programs. The company's ability to secure favorable reimbursement coverage will be crucial, as cystic fibrosis treatments often require lifelong therapy, making payer acceptance essential for commercial success.
Competitive moat
Sionna's competitive moat appears relatively narrow in the current landscape, facing significant challenges from established competitors. The company operates in a space dominated by Vertex Pharmaceuticals, which has built a substantial moat through multiple approved CFTR modulators, extensive patent protection, deep clinical expertise, and established relationships with the cystic fibrosis community. The company's potential moat would need to come from superior efficacy or safety profiles compared to existing treatments, coverage of CFTR mutations not adequately addressed by current therapies, or novel mechanisms of action that provide differentiated benefits. However, without detailed information about Sionna's specific drug candidates or clinical trial results, it's difficult to assess whether such differentiation exists. Intellectual property protection could provide some defensive positioning, but the CFTR modulator space is already crowded with patents, potentially limiting freedom to operate. The specialized nature of cystic fibrosis drug development does create some barriers to entry, requiring deep disease expertise, specialized clinical trial capabilities, and relationships with cystic fibrosis treatment centers. The primary competitive threats come from Vertex's continued innovation and pipeline expansion, potential biosimilar or generic competition as patents expire, and other biotechnology companies developing next-generation CFTR modulators. Additionally, gene therapy approaches being developed by various companies could potentially offer curative treatments that would disrupt the entire CFTR modulator market. Sionna's ability to establish a sustainable competitive position will largely depend on demonstrating clear clinical advantages and securing strong intellectual property protection for its specific therapeutic approaches.
Risks & safety
Sionna presents moderate financial risk typical of clinical-stage biotechnology companies, with adequate near-term liquidity but ongoing cash burn concerns. • Cash position and runway: $82.7 million in cash and short-term investments as of Q1 2025, down from $37.8 million in Q4 2024, suggesting recent financing activity • Cash burn rate: Quarterly operating cash outflow of $16.3 million in Q1 2025, implying approximately 5 quarters of runway at current burn rate • Debt levels: Minimal debt with debt-to-equity ratio of 0.027, indicating low leverage risk • Liquidity strength: Exceptional current ratio of 28.7x and quick ratio of 28.7x, demonstrating strong short-term solvency • Valuation concerns: Negative book value and complex valuation metrics due to development-stage status and accumulated losses • Operational losses: Consistent quarterly losses of $15-16 million, with annual losses of $62 million in 2024 • Other considerations: No revenue generation creates dependency on capital markets for continued operations; clinical trial outcomes will be critical for future funding access
Recent development
Based on the available financial data, Sionna appears to be in the clinical development phase with consistent research and development spending patterns. The company has maintained relatively stable quarterly operating cash outflows in the $11-16 million range, suggesting steady progress in clinical programs without major pivots or expansions. The significant increase in cash position from $37.8 million in Q4 2024 to $82.7 million in Q1 2025 indicates the company completed a substantial financing round, likely to fund continued clinical development activities. This capital raise suggests investor confidence in the company's clinical programs and provides extended runway for operations. The company's total assets have grown substantially from $51.9 million at the end of 2023 to $369.7 million in Q1 2025, reflecting not only the cash infusion but also potential increases in intellectual property valuations or other intangible assets related to its drug development programs. The consistent focus on CFTR modulator development, as evidenced by steady R&D spending patterns, suggests the company has remained committed to its core therapeutic strategy without major strategic shifts or diversification into other disease areas.
SION company profile · for informational purposes only — not investment advice.
Track SION with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free